Cargando…

Effects of Probucol on Restenosis after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis

BACKGROUND: Restenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jichen, Li, Menghao, Lu, Hao, Qiao, Weiguang, Xi, Dan, Luo, TianTian, Xiong, Haowei, Guo, Zhigang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405356/ https://www.ncbi.nlm.nih.gov/pubmed/25898372 http://dx.doi.org/10.1371/journal.pone.0124021

Ejemplares similares

In stent restenosis after percutaneous coronary intervention
por: Eyüboğlu, Mehmet
Publicado: (2016)

Effects of probucol on contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention
por: Wang, Yong, et al.
Publicado: (2019)

Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis
por: Meier, Pascal, et al.
Publicado: (2012)

Impact of anemia on in-stent restenosis after percutaneous coronary intervention
por: Hu, Huilin, et al.
Publicado: (2021)

The effect of Huoxue Huayu decoction on restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis
por: Hou, Yi, et al.
Publicado: (2022)

Risk factors associated with intra-stent restenosis after percutaneous coronary intervention
por: Alexandrescu, Dan-Mihai, et al.
Publicado: (2021)

The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention
por: Tang, Long, et al.
Publicado: (2019)

Effect of Pioglitazone in Preventing In-Stent Restenosis after Percutaneous Coronary Intervention in Patients with Type 2 Diabetes: A Meta-Analysis
por: Zhao, Shi-jie, et al.
Publicado: (2016)

Outcomes of Percutaneous Coronary Intervention for In‐Stent Restenosis Versus De Novo Lesions: A Meta‐Analysis
por: Elbadawi, Ayman, et al.
Publicado: (2023)

Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population
por: Zholdybayeva, Elena V., et al.
Publicado: (2016)

Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis
por: Joo, Hyung Joon, et al.
Publicado: (2018)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention
por: Zhang, Gai, et al.
Publicado: (2020)

In-stent restenosis after percutaneous coronary intervention: emerging knowledge on biological pathways
por: Pelliccia, Francesco, et al.
Publicado: (2023)

The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do
por: Wang, Pengfei, et al.
Publicado: (2020)

Predictive Value of COPD History on In-Stent Restenosis in Coronary Arteries Following Percutaneous Coronary Intervention
por: Hou, Ling, et al.
Publicado: (2023)

Calculating the overall risk of within-stent restenosis after multilesion percutaneous coronary intervention
por: Parviz, Yasir, et al.
Publicado: (2013)

An analysis of factors related to the development of in-stent restenosis after percutaneous coronary intervention: Retraction
Publicado: (2020)

Serum Homocysteine Level Predictive Capability for Severity of Restenosis Post Percutaneous Coronary Intervention
por: Guo, Jiqiang, et al.
Publicado: (2022)

Risk factors of in-stent restenosis in patients with diabetes mellitus after percutaneous coronary intervention: A protocol for systematic review and meta-analysis
por: Li, Suiping, et al.
Publicado: (2021)

Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention
por: Zheng, Guo-Hua, et al.
Publicado: (2012)

Arterial stiffness in patients with coronary artery disease: relation with in-stent restenosis following percutaneous coronary intervention
por: Prskalo, Zrinko, et al.
Publicado: (2016)

Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention
por: He, Wenbo, et al.
Publicado: (2021)

SOCS1 gene promoter methylation status is associated with in-stent restenosis after percutaneous coronary intervention
por: Zhou, Liang, et al.
Publicado: (2017)

Safety and Efficacy of Post-Dilation in Percutaneous Coronary Intervention Using Polymer-Free Ultrathin Strut Sirolimus-Probucol Coated Drug-Eluting Stents
por: Shin, Yonghoon, et al.
Publicado: (2023)

The effectiveness of Salvianolate injection for in-stent restenosis after percutaneous coronary intervention: A protocol for systematic review and meta-analysis
por: Zhang, Miao, et al.
Publicado: (2022)

AGTR1rs5186 Polymorphism Is Associated with the Risk of Restenosis after Percutaneous Coronary Intervention: A Meta-Analysis
por: Lv, Feng, et al.
Publicado: (2022)

The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus
por: Lexis, Chris PH, et al.
Publicado: (2009)

The Predictive Value of ΣΔST/ΔHR Index for Restenosis after Percutaneous Coronary Intervention
por: Kim, Chul, et al.
Publicado: (2012)

Variation in the human soluble epoxide hydrolase gene and risk of restenosis after percutaneous coronary intervention
por: Kullmann, Silke, et al.
Publicado: (2009)

Albumin to globulin ratio was associated with in‐stent restenosis and revascularization events after percutaneous coronary intervention
por: Zhang, Rui, et al.
Publicado: (2022)

Relationship between ALDH2 genotype and in-stent restenosis in Chinese Han patients after percutaneous coronary intervention
por: Lv, Lizhi, et al.
Publicado: (2019)

Heme oxygenase-1 gene promoter polymorphisms are associated with coronary heart disease and restenosis after percutaneous coronary intervention: a meta-analysis
por: Zhang, Ming-Ming, et al.
Publicado: (2016)

Clinical characteristics of early and late drug-eluting stent in-stent restenosis and mid-term prognosis after repeated percutaneous coronary intervention
por: Zheng, Jian-Feng, et al.
Publicado: (2020)

Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis
por: Zhu, Decai, et al.
Publicado: (2023)

Coronary restenosis
Publicado: (1993)

A Nomogram for Predicting In-Stent Restenosis Risk in Patients Undergoing Percutaneous Coronary Intervention: A Population-Based Analysis
por: Luo, Yinhua, et al.
Publicado: (2022)

Predictive value of LncRNA on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis
por: Liu, Shengxiang, et al.
Publicado: (2021)

Predictive value of inflammatory factors on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis
por: Chu, Xin, et al.
Publicado: (2021)

Associations between endothelial progenitor cells, clinical characteristics and coronary restenosis in patients undergoing percutaneous coronary artery intervention
por: Montenegro, Fernando S., et al.
Publicado: (2018)

Factors Affecting In-stent Restenosis in Patients Undergoing Percutaneous Coronary Angioplasty
por: Sajadian, Mostafa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mh24oh5hqki0etm0ovkvo9qtre